The global glaucoma therapeutics market was valued at US$ 5,932.6 Mn in 2017 is anticipated to reach US$ 7,659.8 Mn by 2026, expanding at a CAGR of 2.9% from 2018 to 2026.
Albany, NY -- (SBWIRE) -- 11/26/2018 -- Lack of visible symptoms aggravates glaucoma conditions, leading to irreversible loss of vision. Accounted as one of the potent causes of blindness, glaucoma therapeutics development remains indispensable. Pharmaceutical companies are akin on developing apt substitutes to address prevailing bottlenecks associated with conventional glaucoma therapeutics. A new business intelligence report titled, 'Glaucoma Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 – 2026'included in the fast expanding database of Market Research Reports Search Engine (MRRSE) gauges recent market developments and their eventual implications on holistic growth of glaucoma therapeutics market.
For More Information Request Free Sample on Glaucoma Therapeutics Development Market Research Report @ https://www.mrrse.com/sample/2217
Topical Prostaglandins Emerge as Potent Substitutes for Drops
Traditional treatment modes such as drops, pills, and surgeries have certain limitations that hamper glaucoma management and treatment. Aversion towards invasive therapeutics has potentially reduced glaucoma surgeries in the recent past. Side effects associated with drops discourage long term use, thus augmenting glaucoma progression. Additionally, high costs, and inconvenient drug administration further discourage adoption of drops. Leading pharmaceutical companies and premiere research institutes are akin to develop apt substitutes of glaucoma drops to address unmet needs across the globe, thus fuelling growth in glaucoma therapeutics market. Topical prostaglandins are adopted frequently as a substitute for drops in glaucoma therapeutics.
Ivantis Received FDA Approval for MIGS Device, Hydrus Microstent
Emergence of micro-invasive or minimally-invasive glaucoma surgery (MIGS) is likely to set the growth roadmap for glaucoma therapeutics development market. In a recent development, leading ophthalmology drug provider, Ivantis has affirmed the US FDA approval for its MIGS device, Hydrus Microstent, for mild to moderate primary open-angle glaucoma. The micro-sized device is envisioned to reasonably reduce eye pressure and restore normal fluid flow in the eye. The development is expected to mark new growth possibilities in glaucoma therapeutics market.
Asia-Pacific to Remain Lucrative Region in Glaucoma Therapeutics Market
Additionally, in its subsequent sections, this research report on glaucoma therapeutics market collates broad overview of geographical scope comprising Europe, North America, Latin America, Asia-Pacific, and Middle East and Africa as dominant regional fringes in glaucoma therapeutics market.
Browse Complete Detail on Glaucoma Therapeutics Development Market Research Report with TOC @ https://www.mrrse.com/glaucoma-therapeutics-market
Prostaglandins Segment Likely to Witness Maximum Adoption
This detailed research report on glaucoma therapeutics market offers decisive insights on ongoing market drivers, restraints, trends, and opportunities prevalent in glaucoma therapeutics market. The report primarily aims to aid investments decisions of active market participants in glaucoma therapeutics market, also aiming to enlist entry point cues for aspiring market entrants. Further in the course of the report, readers are also presented with elaborate market segmentation comprising drug class and end-user. Based on drug class, glaucoma market is splintered into prostaglandins, beta blockers, alpha agonists, carbonic anhydrase inhibitors, combination medications, and cholinergics. In terms of end-user applications, glaucoma therapeutics market is diversified into hospitals, ophthalmic clinics, and ambulatory surgical centers.
Competition Dashboard: Glaucoma Therapeutics Market
In the trailing sections of the report, readers are also presented with a detailed overview potential market players in glaucoma therapeutics market, complete with their recent developments, product innovation, and market contribution. Key players identified in glaucoma therapeutics market comprise, Allergan plc, Merck & Co., Inc., Novartis AG, Valeant Pharmaceuticals International, Inc., Pfizer Inc., and Aerie Pharmaceuticals Inc.
Enquire about This Report @ https://www.mrrse.com/enquiry/2217
Market Research Reports Search Engine (MRRSE) is an industry-leading database of Market Research Reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.
MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE's repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.
90, State Street
Albany, NY - 12207
(United States) Telephone: +1-518-730-0559